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ABSTRACT
Objective: To compare the cancer risk of cladribine and other disease-modifying drugs (DMDs) in
trials of people with relapsing multiple sclerosis (pwRMS).
Methods: Meta-analysis of phase III trials of licensed DMDs for pwRMS and a phase III trial of
cladribine (CLARITY). Cancer rates were compared using Fisher exact test.
Results: Eleven trials were included. Investigated treatments included cladribine, dimethyl fuma-
rate, fingolimod, teriflunomide, natalizumab, alemtuzumab, and glatiramer acetate. The cancer
rate in the CLARITY treatment group (0.34%) was not increased compared to all other treatment
groups, whether including placebo-controlled trials only (0.6%, p 5 0.4631) or all trials, i.e.,
including those with an active comparator arm (0.67%, p 5 0.3669). No cancer was reported
in the CLARITY placebo group, whereas the combined cancer rate of all other placebo groups was
1.19% (p 5 0.0159). The cancer rate of zero in the CLARITY placebo group was also lower than
that in the phase III trial of cladribine in people with clinically isolated syndrome (ORACLE MS,
2.91%, p 5 0.0012). In fact, no difference was detected between cancer rates in the treatment
groups of CLARITY (0.34%) and ORACLE MS (0.49%) (p 5 0.6546).
Conclusions: Our study does not support an increased cancer risk from cladribine in the doses used
in CLARITY and ORACLEMS, which previously contributed to refusal of market authorization of cla-
dribine in Europe. Longer-term follow-up is required to assess the safety profile of cladribine, as well
as currently licensed DMDs, to definitively assess cancer risk. Neurol Neuroimmunol Neuroinflamm
2015;2:e158; doi: 10.1212/NXI.0000000000000158
GLOSSARY
DMD 5 disease-modifying drug; IFN 5 interferon; MS 5 multiple sclerosis; pwRMS 5 people with relapsing MS.
Multiple sclerosis (MS) is characterized by focal inflammatory demyelination of the CNS.1
Evidence suggests an important role of autoreactive T and B lymphocytes in MS pathophysi-
ology.1 Cladribine is a synthetic purine analogue cytotoxic to lymphocytes and, to a lesser
degree, monocytes and hematopoietic cells.2 As a result, cladribine induces a dose-dependent
reduction of T and B cells lasting months to years. This lymphopenia is thought to underlie its
therapeutic activity in people with relapsing MS (pwRMS). Evidence from a large phase III trial
(CLARITY) in pwRMS suggests cladribine is a highly effective disease-modifying drug (DMD),
with 45% of patients showing no evidence of disease activity after 96 weeks, following 2 courses
of cladribine.3,4 This efficacy is comparable to the most effective DMDs licensed for pwRMS,
including the monoclonal CD52-specific antibody alemtuzumab (Lemtrada).5,6 Like cladribine,
alemtuzumab is an induction treatment given in 2 or more annual treatment cycles. However,
oral cladribine was refused a license by the European Medicines Agency in 2013. A suspected
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increase in cancer risk was a key reason for this
refusal.7 However, the small number of can-
cers observed during CLARITY is not in itself
sufficient to assess cancer risk. We performed a
meta-analysis comparing the cancer risk of cla-
dribine in CLARITY with other DMDs used
for pwRMS.
METHODS Literature search. The terms “phase III” and
“multiple sclerosis” were used for a PubMed search with no time
restriction in March 2014. References of identified articles were
searched for further sources. Studies were eligible for inclusion if
they (1) were phase III trials of DMDs in pwRMS and (2) reported
the rate of neoplasms and cancers observed. Conference abstracts
were excluded as were studies investigating only an acute dose effect
or follow-up studies of previously published phase III trials.
Statistical analysis. The proportion of pwRMS who developed
cancer was extracted from each study. In trials where multiple
doses were tested, the sum total of cancers in all treatment arms
was used. Given the relatively short and very similar duration of
analyzed studies, the proportion of pwRMS in whom cancer
occurred was used as an estimate of the “rate” of cancer. The
95% confidence interval of cancer rates was calculated using the
modified Wald method.8 Two-tailed Fisher exact test was used to
compare cancer rates. The cancer rate in the treatment group of
CLARITY was first compared to the combined cancer rate of all
treatment groups of placebo-controlled phase III trials of other
DMDs. The cancer rate in the placebo group of CLARITY was
then compared to the combined cancer rate of the placebo groups
of all other phase III trials. Study heterogeneity was calculated using
x2 test and publication bias was assessed using a funnel plot. We
also calculated the annualized cancer rate. Significance was set at
p, 0.05. Statistical analysis was performed using GraphPad Prism,
RevMan, and STATA 13.1 (StataCorp, College Station, TX).
Analysis was similarly done using the cancer rates reported in
a recently completed phase III trial on the effect of oral cladribine
on time to conversion to clinically definite MS in patients with a
first demyelinating event (ORACLE MS).9
Furthermore, meta-analysis pooling using a random-effects
model was performed based on risk difference to assess any excess
risk from cladribine. Risk difference was selected as a measure
rather than the more commonly used measures of relative risk
or relative odds because when incidence rates are low and the
comparator arm has zero cases (as in CLARITY), these latter
measures are not reliably estimated.10
RESULTS Including CLARITY, a total of 11 phase
III trials in pwRMS were eligible for inclusion in
the analysis.3,5,6,11–18 DMDs investigated in these studies
were cladribine, dimethyl fumarate, fingolimod, teriflu-
nomide, natalizumab, alemtuzumab, and glatiramer ace-
tate. The CombiRx trial (interferon [IFN]-b-1a plus
glatiramer acetate) was excluded because malignant and
nonmalignant neoplasms were not reported separately.19
Seven of the included studies compared DMD with
placebo; 4 compared DMD with IFN-b-1a. One trial
compared natalizumab as an add-on to IFN-b-1a with
placebo added to IFN-b-1a. Study characteristics,
references, and annualized cancer rate of DMDs
included in the analysis are provided in table e-1 at
Neurology.org/nn.
The cancer rate in the CLARITY treatment group
was 0.34% and thus not different from all other treat-
ment groups of placebo-controlled trials (0.6%, p 5
0.4631). Among these treatment groups, the cancer rate
in CLARITY was the third lowest observed (figure 1).
Among placebo groups, the cancer rate of zero in
CLARITY was the lowest observed and significantly
lower than the combined cancer rate of all other placebo
groups (1.19%, p 5 0.0159; figure 2).
Comparing all trials (i.e., placebo-controlled and
active comparator IFN-b-1a–controlled), no differ-
ence was detected in the cancer rate of CLARITY
treatment arms vs all other trial arms (0.67%, p 5
0.3669; figure 3). No difference in cancer rate was
detected between treatment arms of CLARITY and
ORACLE MS (0.34% vs 0.49%, p 5 0.6546); both
trials used identical doses of cladribine. Comparison
of the total neoplasm rate (including both malignant
Figure 1 Malignancy rates in treatment groups of placebo-controlled trials
Forest plot of malignancy rates in treatment groups from phase III trials with a placebo group.
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and nonmalignant neoplasms) in CLARITY treatment
arms (1.13%) vs ORACLE MS treatment groups
(0.98%) did not reveal any difference (p 5 1). The
CLARITY placebo group had a lower neoplasm rate
(0%) than the ORACLE MS placebo group (2.91%,
p 5 0.0012). No malignancies were reported in the
placebo group of either trial.
Random-effects pooling based on risk difference
indicated a cancer risk profile from the CLARITY
trial comparable to that of other DMDs (cladribine
had a lower risk difference compared to 4 other trials;
figure 4). We further noted that the CLARITY trial
did not indicate a higher risk difference than the other
“induction” DMD, alemtuzumab, in previously
untreated pwRMS in the Cohen 2012 trial. Given
the heterogeneity of treatments, significant heteroge-
neity between trials was detected (I2 5 56.3%, p 5
0.009). Potential publication bias is demonstrated
using a funnel plot (figure 5).
DISCUSSION The main findings of this study are
that (1) the rate of cancer was similar between the
only phase III trial of cladribine and all other phase
III trials of DMDs in pwRMS, and (2) a significant
difference emerged when comparing the placebo
groups of CLARITY (no cancers) with the placebo
arms of all other phase III trials included in this study.
These findings were corroborated by a cancer rate dif-
ference in CLARITY that was comparable to that of
all other phase III trials for DMDs for pwRMS.
Focusing on cancers observed in pwRMS treated
with cladribine in CLARITY (and ORACLE MS)
might lead to the suspicion that cladribine plays a caus-
ative role, given the fact that 3 pwRMS on cladribine
developed cancer whereas none on placebo did. How-
ever, comparison with other DMDs shows that the
number of malignancies in CLARITY was not
increased. Indeed, the cancer rate in CLARITY was
among the lowest observed for any treatment group,
suggesting that the cancers developed on cladribine
are a reflection of the background risk in the popula-
tion. Moreover, the short latency between initiation
of treatment and cancer diagnosis in CLARITY
(#18 months) renders a causal relationship unlikely.
We also note that in contrast to the trials of alemtu-
zumab, cladribine was compared with placebo (rather
than an active comparator). It is impossible to con-
clude whether comparison with placebo exaggerates
the relative excess risk.
Figure 2 Malignancy rates in placebo groups of trials
Forest plot of malignancy rates in placebo groups of phase III trials.
Figure 3 Malignancy rates in treatment groups of trials
Forest plot of malignancy rates in treatment groups of all phase III trials.
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Investigations of the general risk of cancer among
pwRMS in large cohorts reported conflicting results.
In a Danish study using population-based registers
of MS and cancer, there was no evidence of an overall
increased risk of cancer after a diagnosis of MS; how-
ever, they did report a small excess risk of breast can-
cer among women.20 A recent systematic review of
the incidence and prevalence of cancer in MS re-
ported substantial variation in reported estimates
between studies. Overall, the risk of “any” cancer
was most commonly reported to be lower in pwRMS
compared to the general population. Cancer risk ap-
peared to be higher for malignant brain tumors and
for cancers affecting the urinary tract system. How-
ever, potential surveillance bias and variation of age
and sex of pwRMS across studies stand in the way of
more definitive conclusions.21
The data from our meta-analysis of DMDs in
pwRMS are supported by the long-term outcome of
people with leukemia treated with cladribine. In a
20-year follow-up report of 88 patients diagnosed
with hairy cell leukemia before the age of 40, no
increase in the incidence of secondary malignancies
was detected.22 According to the preliminary report
of the 96-week phase II “oral cladribine as add-on to
IFN-b therapy in patients with active multiple sclero-
sis” (ONWARD) trial, in which oral cladribine (dose
3.5 mg/kg) was compared vs placebo as an add-on to
interferon-beta treatment, 1 of 124 patients, a 57-year-
old woman with a 25-year smoking history, developed
squamous cell carcinoma about 2 years following first
cladribine exposure.23 Cladribine administered as an
injection or infusion has previously been investigated
in placebo-controlled phase II trials of varying dosages,
with results demonstrating reduced disease activity (clin-
ically and on MRI) with no reported cancer signal.24
Limitations of our study include the inevitable
variation between trials in terms of sample size, inclu-
sion criteria, follow-up period, and dosing regimens;
the fact that not all phase III trials for approved
DMDs in pwRMS reported data on cancer rates; and
the fact that all cancers were considered together, i.e.,
regardless of affected organ(s). Furthermore, CLARITY
was 2 months shorter than most of the other trials
included, which lasted 2 years. Mathematically, a slightly
lower number of cancers would therefore be expected in
Figure 4 Malignancy risk differences
Forest plot of malignancy risk differences (RDs) using Mantel-Haenszel pooling. Alem 5 alemtuzumab; CI 5 confidence interval; Clad 5 cladribine; Dime 5
dimethyl fumarate; Fing 5 fingolimod; Nata 5 natalizumab; Teri 5 teriflunomide.
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CLARITY due to the shorter observation period. How-
ever, there is no indication that this difference had any
material impact on the results of our meta-analysis.
We also acknowledge that in a randomized trial
such as CLARITY, if the cancer rate is truly “low,”
it should also have been low relative to the placebo
group in its own trial. However, the apparently high
risk in CLARITY relative to placebo may be due to
the use of the risk ratio rather than the
risk difference; the former is inappropriate in this
context because of the zero cases in the CLARITY
placebo group.10 Our meta-analysis of risk differen-
ces, which does not require arbitrary substitutions for
the zeros, suggests that the risk difference for several
other comparable drugs is higher than that in
CLARITY.
Our data suggest that although current evidence
cannot rule out an increased risk of cancer on cladri-
bine, it also cannot confirm that such a risk exists. A
more definitive assessment of cancer risk will only be
feasible through long-term follow-up,25 be it of peo-
ple treated with cladribine (“Prospective observational
long-term safety registry of multiple sclerosis patients
who have participated in cladribine clinical trials”
[PREMIERE]; ClinicalTrials.gov NCT01013350)
or other DMDs. The results of our meta-analysis
should encourage further investigation into the
potential use of cladribine as a DMD for pwRMS.
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